Transgene Biotek Limited (BOM:526139)

Market Cap	208.37M -34.5%
Revenue (ttm)	2.33M +1.7%
Net Income	-19.09M
EPS	-0.25
Shares Out	75.77M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,129
Average Volume	79,159
Open	2.820
Previous Close	2.760
Day's Range	2.680 - 2.980
52-Week Range	1.830 - 5.260
Beta	0.54
RSI	56.02
Earnings Date	Feb 13, 2026

About Transgene Biotek

Transgene Biotek Limited, a biotechnology company, provides research and development services for bulk drugs in India. It offers a portfolio of oncology drugs, oral drug delivery, and biogenerics. The company provides TrabiDHA for use in health food, baby food/formula, health supplement, and chicken and animal feed markets; Tacrolimus, a drug that suppresses the immune system and is used to prevent rejection of transplanted organs; and Orlistat (tetrahydrolipstatin), a lipase inhibitor that blocks about one-third of intestinal fat absorption. T...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1990
• Country: India
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 526139

Financial Performance

In fiscal year 2025, Transgene Biotek's revenue was 2.61 million, an increase of 10.98% compared to the previous year's 2.35 million. Losses were -6.76 million, 3.14% more than in 2024.